Small Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

Primary prostate cancer is generally treatable by androgen deprivation therapy, however, later recurrences of castrate-resistant prostate cancer (CRPC) that is more difficult to treat nearly always occurs due to aberrant re-activation of the androgen receptor (AR). In this study, we report that CRPC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: McClinch, Kimberly, Avelar, Rita A., Callejas, David, Izadmehr, Sudeh, Wiredja, Danica, Perl, Abbey, Sangodkar, Jaya, Kastrinsky, David, Schlatzer, Daniela, Cooper, Maxwell, Kiselar, Janna, Stachnik, Agnes, Yao, Shen, Hoon, Divya, McQuaid, Dan, Zaware, Nilesh, Gong, Yixuan, Brautigan, David, Plymate, Stephen, Sprenger, Cynthia, Oh, William K., Levine, Alice C., Kirschenbaum, Alexander, Sfakianos, John, Sears, Rosalie, DiFeo, Analisa, Ioannou, Yiannis, Ohlmeyer, Michael, Narla, Goutham, Galsky, Matthew D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5899650/
https://ncbi.nlm.nih.gov/pubmed/29358171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-0123
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados